Trials / Completed
CompletedNCT01427751
Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein Occlusion
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 307 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficacy of dexamethasone intravitreal implant (Ozurdex®) compared to ranibizumab (Lucentis®) in patients with branch retinal vein occlusion (BRVO).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | dexamethasone intravitreal implant | Injection of Ozurdex® (dexamethasone intravitreal implant) into the study eye on Day 1 and Month 5. Patients may receive up to one additional treatment, thereafter. |
| BIOLOGICAL | ranibizumab | Injection of Lucentis® (ranibizumab) into the study eye on Day 1 and monthly for five months. Patients will receive additional treatment thereafter based on re-treatment criteria. |
Timeline
- Start date
- 2011-10-11
- Primary completion
- 2014-11-04
- Completion
- 2014-11-04
- First posted
- 2011-09-02
- Last updated
- 2019-04-18
- Results posted
- 2016-02-15
Locations
6 sites across 6 countries: France, Germany, Israel, Italy, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT01427751. Inclusion in this directory is not an endorsement.